<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1497">
  <stage>Registered</stage>
  <submitdate>3/08/2006</submitdate>
  <approvaldate>5/09/2006</approvaldate>
  <actrnumber>ACTRN12606000390583</actrnumber>
  <trial_identification>
    <studytitle>PHX1149 in Patients With Type 2 Diabetes Mellitus</studytitle>
    <scientifictitle>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Postprandial Blood Glucose, Safety and Establish Proof of Concept With PHX1149 in Patients With Type 2 Diabetes Mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Phenomix Corporation, USA: PHX1149-PROT201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study will test a 4-week treatment course of the investigational drug, PHX1149, at doses of 100mg, 200mg or 400mg, orally once daily, in patients with Type 2 diabetes mellitus. </interventions>
    <comparator>The control group will receive matching placebo, orally once daily, for four weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Postprandial blood glucose</outcome>
      <timepoint>On study Days 1 and 28.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting blood glucose and insulin</outcome>
      <timepoint>Throughout the 28-day study period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma insulin, glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide, gastric inhibitory peptide (GIP) and glucagon levels, and peak postprandial glucose.</outcome>
      <timepoint>On study Days 1 and 28.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma PHX1149 levels and percent ex vivo Dipeptidyl peptidase 4 (DPP4) inhibition.</outcome>
      <timepoint>On study Day 28.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Body mass index (BMI) 25 to 40 kg/m2, inclusive; Type 2 diabetes mellitus; current treatment of Type 2 diabetes mellitus = 1500 mg/day of metformin or highest tolerated dose for at least 4 weeks prior to Screening visit; fasting plasma glucose of 118  220 mg/dL, inclusive; HbA1c (which reflects average blood glucose level over the past 2-3 months) 7.5% - 9.5%, inclusive; and a fasting plasma C-peptide greater than 0.26 nmol/L at screening; no Type 1 diabetes mellitus or marked diabetic long-term complications.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>MODY (Mature Onset Diabetes of the Young), insulin dependent type 2 diabetes mellitus, or other unusual or rare forms of diabetes Mellitus; epilepsy; history of diabetic coma or severe hypoglycemic episode during the 6 months prior to screening; history of stroke, myocardial infarction, symptomatic coronary artery disease, angina, congestive heart failure, or arrhythmia during the 12 months prior to screening; inadequately controlled hypertension; gastrointestinal surgery for obesity; current efforts to lose weight; current administration of anti-psychotic medications, products intended to stimulate appetite, central stimulants, androgens, or growth hormone; administration within the past 2 weeks of systemic glucocorticoids; uncontrolled, serious pulmonary, cardiovascular, hematologic, renal, gastrointestinal, endocrine, neurological, immunosuppressive, psychiatric, or urogenital disorder; diseases of the skin and its appendages, the eyes, ears, nose, or throat;  malignancy within the past 5 years; HIV, Hepatitis B, or Hepatitis C; history of alcohol or substance abuse in the past 2 years or an eating disorder in the past 5 years; use of any investigational drug or participation in any investigational study within 30 days prior to screening; relevant laboratory abnormalities.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone/fax/computer</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software (i.e., computerised sequence generation)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Not mandatory</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>7/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>152</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Phenomix Corporation, USA</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Phenomix Corporation</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Novotech (Australia) Pty Ltd</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Not mandatory</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hans-Peter Guler M.D.</name>
      <address>Phenomix Corporation
Suite 200
5871 Oberlin Drive
San Diego CA 92121</address>
      <phone>0011 1 858 731 5212</phone>
      <fax />
      <email>Hans-Peter.Guler@phenomixcorp.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Serena King</name>
      <address>Novotech (Australia) Pty Ltd
19 Harris Street
Pyrmont NSW 2009</address>
      <phone>+61 2 95189600</phone>
      <fax />
      <email>serena.king@novotech-cro.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>